Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Serotonin 1b (5-HT1b) receptor

2

Serotonin 1d (5-HT1d) receptor

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase I

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Migraine

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Fabre, P.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

EPA CompTox

2

FDA UNII

2

PUBCHEM

2

ChEMBL

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DONITRIPTAN HYDROCHLORIDE

XTD13T14MR

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serotonin 1b (5-HT1b) receptor

Serotonin 1d (5-HT1d) receptor

Conditions:

Donitriptan hydrochloride (F 11356) was developed by Pierre Fabre as a brain penetrant 5-HT1B/1D agonist. Which inhibits capsaicin-induced external carotid vasodilation and produces selective carotid vasoconstriction in various animal species. In Jan...

uary 2001, donitriptan had completed phase I trials for migraine and was scheduled to enter phase II development, but before development in phase II, this drug was discontinued.

DONITRIPTAN

70968BVH2J

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serotonin 1b (5-HT1b) receptor

Serotonin 1d (5-HT1d) receptor

Conditions:

Donitriptan hydrochloride (F 11356) was developed by Pierre Fabre as a brain penetrant 5-HT1B/1D agonist. Which inhibits capsaicin-induced external carotid vasodilation and produces selective carotid vasoconstriction in various animal species. In Jan...

uary 2001, donitriptan had completed phase I trials for migraine and was scheduled to enter phase II development, but before development in phase II, this drug was discontinued.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1